Source comparison
Melanotan-1 Bioavailability: Route Comparison
The table below summarises bioavailability, absorption kinetics, and clinical relevance across administration routes. The Professional Assessment column reflects current research consensus. Oral <1% N/A (undetectable) 95%+ clearance None Not viable. Gastric an
This comparison does not assign a generated winner or score.
- The table below summarises bioavailability, absorption kinetics, and clinical relevance across administration routes. The Professional Assessment column reflects current research consensus.
- Oral
- <1%
- N/A (undetectable)
- 95%+ clearance
- None
- Not viable. Gastric and hepatic degradation eliminate systemic delivery regardless of formulation
- Sublingual
- 2–5% (estimated)
- 20–30 min
- Partial bypass
- Minimal
- Buccal mucosa absorption insufficient for therapeutic plasma levels. Research data limited
- Intranasal
- 8–15% (animal models)
- 15–25 min
- Complete bypass
- Theoretical only
- No human pharmacokinetic data. Nasal peptidases likely reduce absorption below animal model predictions
- Subcutaneous
- >95%
- 60–90 min
- Standard research route
- Gold standard. Reproducible kinetics, minimal degradation, established safety profile
- Intramuscular
- 30–45 min
- Alternative for specific protocols
- Faster Tmax than subcutaneous but higher peak variability. Not preferred for dose-response studies
- Intravenous
- 100%
- Immediate
- Acute experimental only
- Requires medical supervision. Used only in controlled pharmacokinetic trials